198 related articles for article (PubMed ID: 32427989)
41. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE; Shi Y; Patel RH; Chen Z; Shah AP; Srivastava RK; Whitlock RS; Ibarra AM; Larson SR; Sarabia SF; Badachhape A; Starosolski Z; Ghaghada KB; Sumazin P; Annis DA; López-Terrada D; Vasudevan SA
Sci Rep; 2021 Feb; 11(1):2967. PubMed ID: 33536467
[TBL] [Abstract][Full Text] [Related]
42. miR-661 downregulates both Mdm2 and Mdm4 to activate p53.
Hoffman Y; Bublik DR; Pilpel Y; Oren M
Cell Death Differ; 2014 Feb; 21(2):302-9. PubMed ID: 24141721
[TBL] [Abstract][Full Text] [Related]
43. Mdmx promotes genomic instability independent of p53 and Mdm2.
Carrillo AM; Bouska A; Arrate MP; Eischen CM
Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
[TBL] [Abstract][Full Text] [Related]
44. Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
Salomao N; Maslah N; Giulianelli A; Drevon L; Aguinaga L; Gu X; Cassinat B; Giraudier S; Fenaux P; Fahraeus R
Br J Haematol; 2023 Apr; 201(2):234-248. PubMed ID: 36546586
[TBL] [Abstract][Full Text] [Related]
45. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.
Xie X; Lozano G; Siddik ZH
Oncogene; 2016 Sep; 35(36):4798-806. PubMed ID: 26876197
[TBL] [Abstract][Full Text] [Related]
46. Distinct roles of Mdm2 and Mdm4 in red cell production.
Maetens M; Doumont G; Clercq SD; Francoz S; Froment P; Bellefroid E; Klingmuller U; Lozano G; Marine JC
Blood; 2007 Mar; 109(6):2630-3. PubMed ID: 17105817
[TBL] [Abstract][Full Text] [Related]
47. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
48. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.
Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F
Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193
[TBL] [Abstract][Full Text] [Related]
49. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.
Egorova O; Lau HH; McGraphery K; Sheng Y
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075226
[TBL] [Abstract][Full Text] [Related]
50. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
Xu C; Fan CD; Wang X
Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
[TBL] [Abstract][Full Text] [Related]
51. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
52. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
53. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
54. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.
Tan BX; Khoo KH; Lim TM; Lane DP
Oncotarget; 2014 Feb; 5(4):933-43. PubMed ID: 24659749
[TBL] [Abstract][Full Text] [Related]
55. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.
Mandke P; Wyatt N; Fraser J; Bates B; Berberich SJ; Markey MP
PLoS One; 2012; 7(8):e42034. PubMed ID: 22870278
[TBL] [Abstract][Full Text] [Related]
57. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.
Zhang S; Lou J; Li Y; Zhou F; Yan Z; Lyu X; Zhao Y
J Med Chem; 2021 Aug; 64(15):10621-10640. PubMed ID: 34286973
[TBL] [Abstract][Full Text] [Related]
58. Loss of oocytes due to conditional ablation of Murine double minute 2 (Mdm2) gene is p53-dependent and results in female sterility.
Livera G; Uzbekov R; Jarrier P; Fouchécourt S; Duquenne C; Parent AS; Marine JC; Monget P
FEBS Lett; 2016 Aug; 590(16):2566-74. PubMed ID: 27364741
[TBL] [Abstract][Full Text] [Related]
59. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
60. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
